Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 4/2016

01-04-2016 | Symposium-in-Writing Paper

CD57 in human natural killer cells and T-lymphocytes

Authors: Hassen Kared, Serena Martelli, Tze Pin Ng, Sylvia L.F. Pender, Anis Larbi

Published in: Cancer Immunology, Immunotherapy | Issue 4/2016

Login to get access

Abstract

The CD57 antigen (alternatively HNK-1, LEU-7, or L2) is routinely used to identify terminally differentiated ‘senescent’ cells with reduced proliferative capacity and altered functional properties. In this article, we review current understanding of the attributes of CD57-expressing T-cells and NK cells in both health and disease and discuss how this marker can inform researchers about their likely functions in human blood and tissues in vivo. While CD57 expression on human lymphocytes indicates an inability to proliferate, these cells also display high cytotoxic potential, and CD57pos NK cells exhibit both memory-like features and potent effector functions. Accordingly, frequencies of CD57-expressing cells in blood and tissues have been correlated with clinical prognosis in chronic infections or various cancers and with human aging. Functional modulation of senescent CD57pos T-cells and mature CD57pos NK cells may therefore represent innovative strategies for protection against human immunological aging and/or various chronic diseases.
Literature
1.
Abo T, Balch CM (1981) A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol 127(3):1024–1029PubMed
2.
Yamamoto S, Oka S, Inoue M, Shimuta M, Manabe T, Takahashi H, Miyamoto M, Asano M, Sakagami J, Sudo K, Iwakura Y, Ono K, Kawasaki T (2002) Mice deficient in nervous system-specific carbohydrate epitope HNK-1 exhibit impaired synaptic plasticity and spatial learning. J Biol Chem 277(30):27227–27231CrossRefPubMed
3.
Focosi D, Bestagno M, Burrone O, Petrini M (2010) CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol 87(1):107–116CrossRefPubMed
4.
Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA (2003) Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101(7):2711–2720CrossRefPubMed
5.
Palmer BE, Blyveis N, Fontenot AP, Wilson CC (2005) Functional and phenotypic characterization of CD57+ CD4+ T cells and their association with HIV-1-induced T cell dysfunction. J Immunol 175(12):8415–8423CrossRefPubMed
6.
Bandres E, Merino J, Vazquez B, Inoges S, Moreno C, Subira ML, Sanchez-Ibarrola A (2000) The increase of IFN-gamma production through aging correlates with the expanded CD8(+high) CD28(−) CD57(+) subpopulation. Clin Immunol 96(3):230–235CrossRefPubMed
7.
8.
Le Priol Y, Puthier D, Lecureuil C, Combadiere C, Debre P, Nguyen C, Combadiere B (2006) High cytotoxic and specific migratory potencies of senescent CD8+ CD57+ cells in HIV-infected and uninfected individuals. J Immunol 177(8):5145–5154CrossRefPubMed
9.
Petrovas C, Chaon B, Ambrozak DR, Price DA, Melenhorst JJ, Hill BJ, Geldmacher C, Casazza JP, Chattopadhyay PK, Roederer M, Douek DC, Mueller YM, Jacobson JM, Kulkarni V, Felber BK, Pavlakis GN, Katsikis PD, Koup RA (2009) Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. J Immunol 183(2):1120–1132CrossRefPubMedPubMedCentral
10.
Akbar AN, Henson SM (2011) Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol 11(4):289–295CrossRefPubMed
11.
Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10(1):29–37CrossRefPubMedPubMedCentral
12.
Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77(8):4911–4927CrossRefPubMedPubMedCentral
13.
Chattopadhyay PK, Betts MR, Price DA, Gostick E, Horton H, Roederer M, De Rosa SC (2009) The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol 85(1):88–97CrossRefPubMedPubMedCentral
14.
Chiang SC, Theorell J, Entesarian M, Meeths M, Mastafa M, Al-Herz W, Frisk P, Gilmour KC, Ifversen M, Langenskiold C, Machaczka M, Naqvi A, Payne J, Perez-Martinez A, Sabel M, Unal E, Unal S, Winiarski J, Nordenskjold M, Ljunggren HG, Henter JI, Bryceson YT (2013) Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production. Blood 121(8):1345–1356CrossRefPubMed
15.
Sadat-Sowti B, Parrot A, Quint L, Mayaud C, Debre P, Autran B (1994) Alveolar CD8+ CD57+ lymphocytes in human immunodeficiency virus infection produce an inhibitor of cytotoxic functions. Am J Respir Crit Care Med 149(4 Pt 1):972–980CrossRefPubMed
16.
De Rosa SC, Mitra DK, Watanabe N, Herzenberg LA, Herzenberg LA, Roederer M (2001) Vdelta1 and Vdelta2 gammadelta T cells express distinct surface markers and might be developmentally distinct lineages. J Leukoc Biol 70(4):518–526PubMed
17.
Vasudev A, Ying CT, Ayyadhury S, Puan KJ, Andiappan AK, Nyunt MS, Shadan NB, Mustafa S, Low I, Rotzschke O, Fulop T, Ng TP, Larbi A (2014) gamma/delta T cell subsets in human aging using the classical alpha/beta T cell model. J Leukoc Biol 96(4):647–655CrossRefPubMed
18.
Henson SM, Lanna A, Riddell NE, Franzese O, Macaulay R, Griffiths SJ, Puleston DJ, Watson AS, Simon AK, Tooze SA, Akbar AN (2014) p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8(+) T cells. J Clin Invest 124(9):4004–4016CrossRefPubMedPubMedCentral
19.
Ouyang Q, Wagner WM, Voehringer D, Wikby A, Klatt T, Walter S, Muller CA, Pircher H, Pawelec G (2003) Age-associated accumulation of CMV-specific CD8+ T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). Exp Gerontol 38(8):911–920CrossRefPubMed
20.
Voehringer D, Koschella M, Pircher H (2002) Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood 100(10):3698–3702CrossRefPubMed
21.
Ibegbu CC, Xu YX, Harris W, Maggio D, Miller JD, Kourtis AP (2005) Expression of killer cell lectin-like receptor G1 on antigen-specific human CD8+ T lymphocytes during active, latent, and resolved infection and its relation with CD57. J Immunol 174(10):6088–6094CrossRefPubMed
22.
McMahon CW, Zajac AJ, Jamieson AM, Corral L, Hammer GE, Ahmed R, Raulet DH (2002) Viral and bacterial infections induce expression of multiple NK cell receptors in responding CD8(+) T cells. J Immunol 169(3):1444–1452CrossRefPubMed
23.
Voehringer D, Blaser C, Brawand P, Raulet DH, Hanke T, Pircher H (2001) Viral infections induce abundant numbers of senescent CD8 T cells. J Immunol 167(9):4838–4843CrossRefPubMed
24.
Vallejo AN (2005) CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev 205:158–169CrossRefPubMed
25.
Ortiz-Suarez A, Miller RA (2002) A subset of CD8 memory T cells from old mice have high levels of CD28 and produce IFN-gamma. Clin Immunol 104(3):282–292CrossRefPubMed
26.
Kared H, Camous X, Larbi A (2014) T cells and their cytokines in persistent stimulation of the immune system. Curr Opin Immunol 29:79–85CrossRefPubMed
27.
Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, Dong T, Chesney G, Waters A, Easterbrook P, Dunbar PR, Shepherd D, Cerundolo V, Emery V, Griffiths P, Conlon C, McMichael AJ, Richman DD, Rowland-Jones SL, Appay V (2004) Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2(2):E20CrossRefPubMedPubMedCentral
28.
Scheinberg P, Melenhorst JJ, Brenchley JM, Hill BJ, Hensel NF, Chattopadhyay PK, Roederer M, Picker LJ, Price DA, Barrett AJ, Douek DC (2009) The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood 114(24):5071–5080CrossRefPubMedPubMedCentral
29.
Maurer T, Ponte M, Leslie K (2007) HIV-associated Kaposi’s sarcoma with a high CD4 count and a low viral load. N Engl J Med 357(13):1352–1353CrossRefPubMed
30.
Weekes MP, Wills MR, Mynard K, Hicks R, Sissons JGP, Carmichael AJ (1999) Large clonal expansions of human virus-specific memory cytotoxic T lymphocytes within the CD57(+) CD28(−) CD8(+) T-cell population. Immunology 98(3):443–449CrossRefPubMedPubMedCentral
31.
Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Lofgren S, Nilsson BO, Ernerudh J, Pawelec G, Johansson B (2005) An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 60(5):556–565CrossRefPubMed
32.
Franceschi C, Bonafe M, Valensin S (2000) Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine 18(16):1717–1720CrossRefPubMed
33.
Wertheimer AM, Bennett MS, Park B, Uhrlaub JL, Martinez C, Pulko V, Currier NL, Nikolich-Zugich D, Kaye J, Nikolich-Zugich J (2014) Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans. J Immunol 192(5):2143–2155CrossRefPubMedPubMedCentral
34.
Dolfi DV, Mansfield KD, Polley AM, Doyle SA, Freeman GJ, Pircher H, Schmader KE, Wherry EJ (2013) Increased T-bet is associated with senescence of influenza virus-specific CD8 T cells in aged humans. J Leukoc Biol 93(6):825–836CrossRefPubMedPubMedCentral
35.
Characiejus D, Pasukoniene V, Kazlauskaite N, Valuckas KP, Petraitis T, Mauricas M, Den Otter W (2002) Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res 22(6B):3679–3683PubMed
36.
Characiejus D, Ukoniene VP, Auskaite RJ, Azlauskaite N, Aleknavicius E, Mauricas M, Den Otter W (2008) Peripheral blood CD8highCD57+ lymphocyte levels may predict outcome in melanoma patients treated with adjuvant interferon-alpha. Anticancer Res 28(2B):1139–1142PubMed
37.
Akagi J, Baba H (2008) Prognostic value of CD57(+) T lymphocytes in the peripheral blood of patients with advanced gastric cancer. Int J Clin Oncol 13(6):528–535CrossRefPubMed
38.
Characiejus D, Pasukoniene V, Jacobs JJ, Eidukevicius R, Jankevicius F, Dobrovolskiene N, Mauricas M, Van Moorselaar RJ, Den Otter W (2011) Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2. Anticancer Res 31(2):699–703PubMed
39.
Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P, Villaggio B, Ferrera A, Kunkl A, Rizzi M, Ferrera F, Balestra P, Ghio M, Contini P, Setti M, Olive D, Azzarone B, Carmignani G, Ravetti JL, Torre G, Indiveri F (2007) CD8+ CD28− T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 179(7):4323–4334CrossRefPubMed
40.
Gutkin DW, Shurin MR (2014) Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother 63(1):45–57CrossRefPubMedPubMedCentral
41.
Tsukishiro T, Donnenberg AD, Whiteside TL (2003) Rapid turnover of the CD8(+) CD28(−) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother 52(10):599–607CrossRefPubMed
42.
Van den Hove LE, Vandenberghe P, Van Gool SW, Ceuppens JL, Demuynck H, Verhoef GE, Boogaerts MA (1998) Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment. Leuk Res 22(2):175–184CrossRefPubMed
43.
Atayar C, Poppema S, Visser L, van den Berg A (2006) Cytokine gene expression profile distinguishes CD4+/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin’s lymphoma from their tonsillar counterparts. J Pathol 208(3):423–430CrossRefPubMed
44.
Serrano D, Monteiro J, Allen SL, Kolitz J, Schulman P, Lichtman SM, Buchbinder A, Vinciguerra VP, Chiorazzi N, Gregersen PK (1997) Clonal expansion within the CD4+ CD57+ and CD8+ CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol 158(3):1482–1489PubMed
45.
Sze DM, Brown RD, Yuen E, Gibson J, Ho J, Raitakari M, Basten A, Joshua DE, de St Fazekas, Groth B (2003) Clonal cytotoxic T cells in myeloma. Leuk Lymphoma 44(10):1667–1674CrossRefPubMed
46.
Mileshkin L, Honemann D, Gambell P, Trivett M, Hayakawa Y, Smyth M, Beshay V, Ritchie D, Simmons P, Milner AD, Zeldis JB, Prince HM (2007) Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. Haematologica 92(8):1075–1082CrossRefPubMed
47.
Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C (2012) Expansion of a CD8(+) PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res 18(3):678–687CrossRefPubMed
48.
Dobrovolskiene NT, Cicenas S, Kazlauskaite N, Miseikyte-Kaubriene E, Krasko JA, Ostapenko V, Pasukoniene V, Strioga MM (2015) CD8CD57 T-cell population as an independent predictor of response to chemoradiation therapy in extensive-stage small cell lung cancer. Lung Cancer 90(2):326–333CrossRefPubMed
49.
Bottomley M, Harden P, Wood K (2015) CD57 expression in CD8 T cells and development of cutaneous squamous cell carcinoma in renal transplant recipients: a prospective cohort study. Lancet 385(Suppl 1):S23CrossRefPubMed
50.
Lin YX, Yan LN, Li B, Wang LL, Wen TF, Zeng Y, Wang WT, Zhao JC, Yang JY, Xu MQ, Ma YK, Chen ZY, Bai YJ (2009) A significant expansion of CD8+ CD28− T-suppressor cells in adult-to-adult living donor liver transplant recipients. Transplant Proc 41(10):4229–4231CrossRefPubMed
51.
Vlad G, Cortesini R, Suciu-Foca N (2008) CD8+ T suppressor cells and the ILT3 master switch. Hum Immunol 69(11):681–686CrossRefPubMed
52.
Sabnani I, Zucker MJ, Tsang P, Palekar S (2006) Clonal T-large granular lymphocyte proliferation in solid organ transplant recipients. Transplant Proc 38(10):3437–3440CrossRefPubMed
53.
Nielsen CM, White MJ, Goodier MR, Riley EM (2013) Functional Significance of CD57 Expression on human NK Cells and relevance to disease. Front Immunol 4:422CrossRefPubMedPubMedCentral
54.
Mikulkova Z, Praksova P, Stourac P, Bednarik J, Strajtova L, Pacasova R, Belobradkova J, Dite P, Michalek J (2010) Numerical defects in CD8+ CD28− T-suppressor lymphocyte population in patients with type 1 diabetes mellitus and multiple sclerosis. Cell Immunol 262(2):75–79CrossRefPubMed
55.
Tulunay A, Yavuz S, Direskeneli H, Eksioglu-Demiralp E (2008) CD8+ CD28−, suppressive T cells in systemic lupus erythematosus. Lupus 17(7):630–637CrossRefPubMed
56.
Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL (2010) CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116(19):3865–3874CrossRefPubMedPubMedCentral
57.
Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, Bjorklund AT, Flodstrom-Tullberg M, Michaelsson J, Rottenberg ME, Guzman CA, Ljunggren HG, Malmberg KJ (2010) Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116(19):3853–3864CrossRefPubMed
58.
Brunetta E, Hudspeth KL, Mavilio D (2010) Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. J Leukoc Biol 88(6):1119–1130CrossRefPubMed
59.
60.
Strauss-Albee DM, Horowitz A, Parham P, Blish CA (2014) Coordinated regulation of NK receptor expression in the maturing human immune system. J Immunol 193(10):4871–4879CrossRefPubMedPubMedCentral
61.
62.
Mela CM, Goodier MR (2007) The contribution of cytomegalovirus to changes in NK cell receptor expression in HIV-1-infected individuals. J Infect Dis 195(1):158–159; author reply 159-160
63.
Guma M, Cabrera C, Erkizia I, Bofill M, Clotet B, Ruiz L, Lopez-Botet M (2006) Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis 194(1):38–41CrossRefPubMed
64.
65.
Prod’homme V, Griffin C, Aicheler RJ, Wang EC, McSharry BP, Rickards CR, Stanton RJ, Borysiewicz LK, Lopez-Botet M, Wilkinson GW, Tomasec P (2007) The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1− NK cells. J Immunol 178(7):4473–4481CrossRefPubMedPubMedCentral
66.
Goodier MR, White MJ, Darboe A, Nielsen CM, Goncalves A, Bottomley C, Moore SE, Riley EM (2014) Rapid NK cell differentiation in a population with near-universal human cytomegalovirus infection is attenuated by NKG2C deletions. Blood 124(14):2213–2222CrossRefPubMedPubMedCentral
67.
Hendricks DW, Balfour HH Jr, Dunmire SK, Schmeling DO, Hogquist KA, Lanier LL (2014) Cutting edge: NKG2C(hi)CD57+ NK cells respond specifically to acute infection with cytomegalovirus and not Epstein–Barr virus. J Immunol 192(10):4492–4496CrossRefPubMedPubMedCentral
68.
White MJ, Nielsen CM, McGregor RH, Riley EH, Goodier MR (2014) Differential activation of CD57-defined natural killer cell subsets during recall responses to vaccine antigens. Immunology 142(1):140–150CrossRefPubMedPubMedCentral
69.
Ahmad F, Hong HS, Jackel M, Jablonka A, Lu IN, Bhatnagar N, Eberhard JM, Bollmann BA, Ballmaier M, Zielinska-Skowronek M, Schmidt RE, Meyer-Olson D (2014) High frequencies of polyfunctional CD8+ NK cells in chronic HIV-1 infection are associated with slower disease progression. J Virol 88(21):12397–12408CrossRefPubMedPubMedCentral
70.
Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, Marcenaro E, Moretta A, Mavilio D (2009) The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood 114(18):3822–3830CrossRefPubMedPubMedCentral
71.
Zhao JJ, Pan QZ, Pan K, Weng DS, Wang QJ, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC (2014) Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells. Sci Rep 4:5177PubMedPubMedCentral
72.
Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, Houchins JP, Miller S, Kang SM, Norris PJ, Nixon DF, Lanier LL (2011) Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA 108(36):14725–14732CrossRefPubMedPubMedCentral
73.
Bhatnagar N, Ahmad F, Hong HS, Eberhard J, Lu IN, Ballmaier M, Schmidt RE, Jacobs R, Meyer-Olson D (2014) FcgammaRIII (CD16)-mediated ADCC by NK cells is regulated by monocytes and FcgammaRII (CD32). Eur J Immunol 44(11):3368–3379CrossRefPubMed
74.
Holmes TD, Wilson EB, Black EV, Benest AV, Vaz C, Tan B, Tanavde VM, Cook GP (2014) Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT. Proc Natl Acad Sci USA 111(52):E5688–E5696CrossRefPubMedPubMedCentral
75.
Le Garff-Tavernier M, Beziat V, Decocq J, Siguret V, Gandjbakhch F, Pautas E, Debre P, Merle-Beral H, Vieillard V (2010) Human NK cells display major phenotypic and functional changes over the life span. Aging Cell 9(4):527–535CrossRefPubMed
76.
Borysiewicz LK, Rodgers B, Morris S, Graham S, Sissons JG (1985) Lysis of human cytomegalovirus infected fibroblasts by natural killer cells: demonstration of an interferon-independent component requiring expression of early viral proteins and characterization of effector cells. J Immunol 134(4):2695–2701PubMed
77.
Lima JF, Oliveira LM, Pereira NZ, Mitsunari GE, Duarte AJ, Sato MN (2014) Distinct natural killer cells in HIV-exposed seronegative subjects with effector cytotoxic CD56(dim) and CD56(bright) cells and memory-like CD57(+) NKG2C(+) CD56(dim) cells. J Acquir Immune Defic Syndr 67(5):463–471CrossRefPubMed
78.
Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12(4):239–252CrossRefPubMed
79.
Balch CM, Tilden AB, Dougherty PA, Cloud GA (1983) Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg 198(2):192–199CrossRefPubMedPubMedCentral
80.
Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, Tallerico R, Santinami M, Gulletta E, Ietto C, Galgani M, Matarese G, Bifulco M, Ferrone S, Colucci F, Moretta A, Karre K, Carbone E (2014) Enrichment of CD56(dim)KIR+ CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat Commun 5:5639CrossRefPubMedPubMedCentral
81.
Matsumura G (1990) Leu7 (HNK-1)-positive cells in peripheral blood and natural killer cell activity in patients with atopic dermatitis. Nihon Hifuka Gakkai Zasshi 100(1):57–62PubMed
82.
Batista MD, Ho EL, Kuebler PJ, Milush JM, Lanier LL, Kallas EG, York VA, Chang D, Liao W, Unemori P, Leslie KS, Maurer T, Nixon DF (2013) Skewed distribution of natural killer cells in psoriasis skin lesions. Exp Dermatol 22(1):64–66CrossRefPubMedPubMedCentral
83.
Ottaviani C, Nasorri F, Bedini C, de Pita O, Girolomoni G, Cavani A (2006) CD56brightCD16(−) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 36(1):118–128CrossRefPubMed
84.
Dalbeth N, Callan MF (2002) A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum 46(7):1763–1772CrossRefPubMed
85.
Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, Mosca F, Boggi U, Muda AO, Del Prato S, Elliott JF, Covacci A, Rappuoli R, Roep BO, Marchetti P (2007) Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA 104(12):5115–5120CrossRefPubMedPubMedCentral
86.
van Helden MJ, Goossens S, Daussy C, Mathieu AL, Faure F, Marcais A, Vandamme N, Farla N, Mayol K, Viel S, Degouve S, Debien E, Seuntjens E, Conidi A, Chaix J, Mangeot P, de Bernard S, Buffat L, Haigh JJ, Huylebroeck D, Lambrecht BN, Berx G, Walzer T (2015) Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection. J Exp Med 212(12):2015–2025. doi:10.​1084/​jem.​20150809 CrossRefPubMed
87.
Omilusik KD, Best JA, Yu B, Goossens S, Weidemann A, Nguyen JV, Seuntjens E, Stryjewska A, Zweier C, Roychoudhuri R, Gattinoni L, Bird LM, Higashi Y, Kondoh H, Huylebroeck D, Haigh J, Goldrath AW (2015) Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory T cell populations during infection. J Exp Med 212(12):2027–2039. doi:10.​1084/​jem.​20150194 CrossRefPubMed
88.
Lee SA, Sinclair E, Jain V, Huang Y, Epling L, Van Natta M, Meinert CL, Martin JN, McCune JM, Deeks SG, Lederman MM, Hecht FM, Hunt PW (2014) Low proportions of CD28− CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis 210(3):374–382CrossRefPubMedPubMedCentral
89.
Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, McCune JM, Moreno S, Deeks SG (2014) HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 10(5):e1004078CrossRefPubMedPubMedCentral
90.
Di Mitri D, Azevedo RI, Henson SM, Libri V, Riddell NE, Macaulay R, Kipling D, Soares MV, Battistini L, Akbar AN (2011) Reversible senescence in human CD4+ CD45RA+ CD27− memory T cells. J Immunol 187(5):2093–2100CrossRefPubMed
91.
Henson SM, Macaulay R, Riddell NE, Nunn CJ, Akbar AN (2015) Blockade of PD-1 or p38 MAP kinase signaling enhances senescent human CD8(+) T-cell proliferation by distinct pathways. Eur J Immunol 45(5):1441–1451CrossRefPubMed
92.
Libri V, Azevedo RI, Jackson SE, Di Mitri D, Lachmann R, Fuhrmann S, Vukmanovic-Stejic M, Yong K, Battistini L, Kern F, Soares MV, Akbar AN (2011) Cytomegalovirus infection induces the accumulation of short-lived, multifunctional CD4+ CD45RA+ CD27+ T cells: the potential involvement of interleukin-7 in this process. Immunology 132(3):326–339CrossRefPubMedPubMedCentral
93.
Lanna A, Coutavas E, Levati L, Seidel J, Rustin MH, Henson SM, Akbar AN, Franzese O (2013) IFN-alpha inhibits telomerase in human CD8(+) T cells by both hTERT downregulation and induction of p38 MAPK signaling. J Immunol 191(7):3744–3752CrossRefPubMed
Metadata
Title
CD57 in human natural killer cells and T-lymphocytes
Authors
Hassen Kared
Serena Martelli
Tze Pin Ng
Sylvia L.F. Pender
Anis Larbi
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 4/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-016-1803-z

Other articles of this Issue 4/2016

Cancer Immunology, Immunotherapy 4/2016 Go to the issue

Symposium-in-writing paper

Selection and expansion of natural killer cells for NK cell-based immunotherapy

Original Article

A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17+ cell frequency

Original Article

A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2

Original Article

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node

Symposium-in-Writing Paper

Killer-cell immunoglobulin-like receptor genes and ligands and their role in hematologic malignancies

Symposium-in-writing paper

Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits